Video

Bobby Green: Communicating With Oncologists Increases Understanding of Clinic Needs

By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.

By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.

Transcript

How important is it for Flatiron to collaborate with oncologists who are at the forefront of care to better understand what features should be included to enhance clinical workflow?

So, if I’ve learned nothing in my 5 plus years at Flatiron, is that you really don’t know what the right things to do are unless you actually talk to the people who are doing it and go spend time with them. So, at Flatiron what that means is talking to oncologists, asking them questions, understanding what their pain points are, going to their clinics, observing what actually happens while they’re seeing patients, and we do a ton of that at Flatiron. We have teams that go out and spend time with practices and understand their workflows. It’s just 1 of those things that there’s no right answer. Different practices do things differently, so you have to assimilate that information and use that sort of frontline experience to better understand—how do you use technology to solve those problems.

Related Videos
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Dr Margrit Wiesendanger
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Eboni Price-Haywood, MD, and Toni Flowers, PhD
Tom Belmon, CAP, GPBCH
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Tom Belmont
Pieter Sonneveld, MD, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo